14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ATYR vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ATYR carries a Unified Composite Score of 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin), whereas SRZN carries 33.2/100 (SELL) at $30.16 (N/M Forward P/E, -485.4% operating margin).
Growth vs. Quality Trade-Off: ATYR earns the overall head-to-head edge with a stronger Unified Composite Score (34.3/100 SELL vs. SRZN 33.2/100 SELL) and -9.67β · 13806% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ATYR (34.3/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ATYR vs SRZN Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ATYR carries a Unified Composite Score of 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin), whereas SRZN carries 33.2/100 (SELL) at $30.16 (N/M Forward P/E, -485.4% operating margin). Growth vs. Quality Trade-Off: ATYR earns the overall head-to-head edge with a stronger Unified Composite Score (34.3/100 SELL vs. SRZN 33.2/100 SELL) and -9.67β · 13806% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ATYR (34.3/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SRZN leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), ATYR cumulative revenue shifted +0.0% while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
SRZN screens cheaper on headline valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 70% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.